All In MedTech

Device Trial Radar · NCT05806216

Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD)

A Prospective, Multi-Center Study of Dynamic Quantification of Social-Visual Engagement (DQSVE) in Autism Spectrum Disorder (ASD): Diagnosis and Assessment For Children

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

929

Actual

Start

Aug 23, 2023

Primary completion

Mar 27, 2025

Study completion Aug 31, 2025

Sponsor

Lead sponsor
EarliTec Diagnostics, IncNot on our public-company list
Sponsor type
Industry
First posted
Apr 10, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 31 months, up to 84 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn about the utility and performance of the EarliPoint System (™): Evaluation for Autism Spectrum Disorder to diagnose and assess autism spectrum disorder (ASD) in children ages 31-96 months (2.5 - 7 years chronological age). The main questions it aims to answer are: 1. To determine the sensitivity and specificity of the EarliPoint device (test) compared to Expert Clinician Diagnosis (ECD) using gold-standard clinical reference assessments in the target age-expanded population. 2. To determine the association between the EarliPoint Verbal Ability Index score and the clinical measures of verbal ability as measured by the Differential Ability Scales (DAS-II). 3. To determine the association between the EarliPoint Nonverbal Ability Index score and the clinical measures of non-verbal abilities as measured by the Differential Ability Scales (DAS-II). 4. To determine the association between the EarliPoint Social Disability Index score and the Autism Diagnostic Observation Schedule, second edition (ADOS-II) Overall Total Score. 5. To determine the association between the EarliPoint Expressive Language Ability Index score and the clinical measures of verbal ability as measured by the Differential Ability Scales (DAS-II). 6. To determine the association between the EarliPoint Receptive Language Ability Index score and the clinical measures of verbal ability as measured by the Differential Ability Scales (DAS-II). 7. To estimate the incidence of adverse device effects associated with the use of the EarliPoint device.

Conditions

  • Autism Spectrum Disorder
  • Autism

Interventions

  • EarliPoint DiagnosisDevice

    Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder

  • Clinically Certain Expert Clinician Diagnosis (CC-ECD)Behavioral

    Diagnosis by an expert clinician using gold standard developmental assessment tools.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EarliPoint sensitivityTime frame: at baseline
  2. EarliPoint specificityTime frame: at baseline

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Southwest Autism Research and Resource Center

    Phoenix, Arizona

  • Emory University - Marcus Autism Center

    Altanta, Georgia

  • University of Iowa

    Iowa City, Iowa

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.